Investor Presentation - First Six Months of 2021

71 Investor presentation First six months of 2021 Solid commercial execution is driving NorditropinⓇ sales growth Historic reported sales for NorditropinⓇ DKK 40% billion 8% 14% -22% 7% 2% 8% 9 30% 6 3 20% 10% NorditropinⓇ value leadership maintained despite increasing competition 35.9% 0 0% 2015 2016 2017 2018 2019 2020 May 2016 Ⓡ Norditropin Growth at CER Novo Nordisk Eli Lilly ⚫Pfizer May 2021 Roche Merck Kgaa -Other Sandoz Note: Company reported sales; CER: Constant exchange rates Note: IQVIA, MAT value DKK, May 2021 Novo NordiskⓇ Continue frequent launches with new indications and device upgrades Device portfolio norditropin simpleXx somatropin (rDNA origin) injection norditropin flexpro somatropin (rDNA origin injection norditropin nordilet somatropin (rDNA origin) injection norditropin nordiflex™ somatropin (rDNA origin) injection

View entire presentation